{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:16:07Z","timestamp":1781082967020,"version":"3.54.1"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.1001\/jamaophthalmol.2020.0437","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T15:01:52Z","timestamp":1584630112000},"page":"510","source":"Crossref","is-referenced-by-count":22,"title":["Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial"],"prefix":"10.1001","volume":"138","author":[{"given":"Ebenezer","family":"Daniel","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan E.","family":"Grunwald","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Toth","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Martin","sequence":"additional","affiliation":[{"name":"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-shuang","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Comparison of Age-Related Macular Degeneration Treatments Trials Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"eoi200015r2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"eoi200015r3","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi200015r4","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration.","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200015r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye (Lond)"},{"issue":"1","key":"eoi200015r6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials.","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200015r7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200015r8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200015r9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2014.09.012","article-title":"Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes.","volume":"159","author":"Channa","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"eoi200015r10","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1111\/aos.13157","article-title":"Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.","volume":"94","author":"Munk","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"eoi200015r11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT.","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi200015r12","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.ophtha.2013.03.029","article-title":"Incidence and progression of geographic atrophy.","volume":"120","author":"Joachim","year":"2013","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi200015r13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1097\/IAE.0b013e3181b1baeb","article-title":"Risk factors for second eye progression to advanced age-related macular degeneration: SST report No. 21 Submacular Surgery Trials Research Group.","volume":"29","author":"Solomon","year":"2009","journal-title":"Retina"},{"issue":"9","key":"eoi200015r14","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.ophtha.2008.03.008","article-title":"Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial.","volume":"115","author":"Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group","year":"2008","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi200015r15","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ophtha.2007.08.030","article-title":"Retinal precursors and the development of geographic atrophy in age-related macular degeneration.","volume":"115","author":"Klein","year":"2008","journal-title":"Ophthalmology"},{"issue":"Pt 5","key":"eoi200015r16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/eye.1988.106","article-title":"Evolution of geographic atrophy of the retinal pigment epithelium.","volume":"2","author":"Sarks","year":"1988","journal-title":"Eye (Lond)"},{"issue":"8","key":"eoi200015r17","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00417-019-04373-4","article-title":"Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion.","volume":"257","author":"Kim","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"eoi200015r18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajo.2015.09.032","article-title":"Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab Treatment.","volume":"161","author":"Kuroda","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi200015r19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ajo.2015.02.020","article-title":"Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration.","volume":"159","author":"Sch\u00fctze","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi200015r20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial.","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi200015r21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ophtha.2018.11.020","article-title":"Five-year follow-up of nonfibrotic scars in the comparison of age-related macular degeneration treatments trials.","volume":"126","author":"Daniel","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi200015r22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the comparison of age-related macular degeneration treatments trials.","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi200015r23","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials.","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi200015r24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials.","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200015r25","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials.","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi200015r26","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi200015r27","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.ophtha.2012.02.013","article-title":"Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials.","volume":"119","author":"Grunwald","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"eoi200015r28","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.ophtha.2012.06.040","article-title":"Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials.","volume":"119","author":"DeCroos","year":"2012","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200015r29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1136\/bjo.2005.084830","article-title":"Choroidal neovascularisation and atrophy.","volume":"90","author":"Sunness","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"eoi200015r30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s10384-019-00680-9","article-title":"Pseudodrusen pattern and development of late age-related macular degeneration in the fellow eye of the unilateral case.","volume":"63","author":"Sakurada","year":"2019","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"eoi200015r31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","article-title":"Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation.","volume":"159","author":"Cho","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"eoi200015r32","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ophtha.2016.02.043","article-title":"Pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatments trials.","volume":"123","author":"Zhou","year":"2016","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi200015r33","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200015r34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration.","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200015r35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.oret.2018.11.011","article-title":"Distribution of OCT features within areas of macular atrophy or scar after 2 years of anti-VEGF treatment for neovascular AMD in CATT.","volume":"3","author":"Toth","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"eoi200015r1","unstructured":"American Academy of Ophthalmology Retina\/Vitreous Panel. Age-related macular degeneration PPP 2019. Published 2015. Accessed February 18, 2020. https:\/\/www.aao.org\/preferred-practice-pattern\/age-related-macular-degeneration-ppp"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2762852\/jamaophthalmology_daniel_2020_oi_200015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T03:12:11Z","timestamp":1589512331000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2762852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.0437","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}